ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P 500
5,667.20
0.64%
US Tech 100
19,596.80
-1.29%
Dow Jones
40,954.48
1.85%
Brent Oil
83.255
-0.07%
Bitcoin
65,310.37
0.34%
Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Vicuron Pharmaceuticals (MM) (MICU)

  7. Vicuron Pharmaceuticals (MM) (MICU) News

MICU

Vicuron (MICU)

Vicuron Pharmaceuticals (MM)
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:MICU
DateTimeSourceHeadlineSymbolCompany
09/14/20054:00AMPR Newswire (US)Pfizer Completes Acquisition of Vicuron PharmaceuticalsNASDAQ:MICU
09/11/20051:00PMPR Newswire (US)Vicuron Pharmaceuticals - Announces Expiration of Hart-Scott-Rodino Act Waiting Period and Expected Closing Date for AcquisitionNASDAQ:MICU
08/18/20055:30PMPR Newswire (US)Vicuron Pharmaceuticals Files New Drug Application (NDA) for Anidulafungin for Treatment of Invasive Candidiasis/CandidemiaNASDAQ:MICU
08/15/20055:30PMPR Newswire (US)Vicuron Pharmaceuticals Stockholders Approve Merger With PfizerNASDAQ:MICU
08/04/20055:30PMPR Newswire (US)Vicuron Pharmaceuticals Announces Second Quarter 2005 Financial ResultsNASDAQ:MICUVicuron Pharmaceuticals (MM)
06/16/20052:00AMPR Newswire (US)Pfizer to Acquire Vicuron Pharmaceuticals to Extend its Research Commitment in Anti-InfectivesNASDAQ:MICUVicuron Pharmaceuticals (MM)
06/02/20053:00AMPR Newswire (US)Vicuron Pharmaceuticals Receives Issued Patent for Dalbavancin Dosing by U.S. Patent and Trademark OfficeNASDAQ:MICU
05/31/20053:00AMPR Newswire (US)Vicuron Pharmaceuticals Files Amendment to Anidulafungin New Drug Application (NDA) for Treatment of Esophageal CandidiasisNASDAQ:MICU
05/26/20055:30PMPR Newswire (US)Vicuron Pharmaceuticals to Present at the Friedman Billings Ramsey 9th Annual Growth Investor Conference and the Pacific GrowthNASDAQ:MICU
05/17/20055:30PMPR Newswire (US)Vicuron Pharmaceuticals to Present at the 2005 Needham Biotech ConferenceNASDAQ:MICU
05/11/20053:00AMPR Newswire (US)Vicuron Pharmaceuticals Announces Extension of FDA Review of Dalbavancin New Drug ApplicationNASDAQ:MICU
05/09/20055:30PMPR Newswire (US)Vicuron Pharmaceuticals to Present at the Bear Stearns 2005 Healthcare Conference and the Banc of America Securities HealthcareNASDAQ:MICU
05/05/20055:30PMPR Newswire (US)Vicuron Pharmaceuticals Announces First Quarter 2005 Financial ResultsNASDAQ:MICU
04/28/20058:30AMPR Newswire (US)Vicuron Pharmaceuticals to Present at Morgan Stanley Healthcare Unplugged ConferenceNASDAQ:MICU
03/30/20055:30PMPR Newswire (US)Vicuron Pharmaceuticals Extends Pfizer Deal to Develop Oral Antibiotics for Community MarketNASDAQ:MICU
03/10/20054:30PMPR Newswire (US)Vicuron Pharmaceuticals Announces Fourth Quarter 2004 Financial ResultsNASDAQ:MICU
03/10/20057:30AMPR Newswire (US)Vicuron Pharmaceuticals to Present at the SG Cowen & Co. 25th Annual Health Care ConferenceNASDAQ:MICU
03/04/20052:00AMPR Newswire (US)Vicuron Pharmaceuticals Provides Update on Novartis Peptide Deformylase Inhibitor ProgramNASDAQ:MICU
02/25/20057:30AMPR Newswire (US)Vicuron Pharmaceuticals to Present at the Wells Fargo Securities Healthcare ConferenceNASDAQ:MICU
02/24/20052:00AMPR Newswire (US)Vicuron Pharmaceuticals Granted Priority Review of Dalbavancin NDA by FDA in Complicated Skin and Soft Tissue InfectionsNASDAQ:MICU
02/17/20057:30AMPR Newswire (US)Vicuron Pharmaceuticals to Present at the BIO CEO & Investor Conference 2005NASDAQ:MICU
02/07/20052:00AMPR Newswire (US)Vicuron Pharmaceuticals Announces Phase 3 Trial Results Demonstrate Superiority of Anidulafungin Versus Fluconazole in InvasiveNASDAQ:MICU
01/24/20052:00AMPR Newswire (US)Vicuron Pharmaceuticals Promotes David S. Krause, M.D., to Executive Vice President and Chief Medical OfficerNASDAQ:MICU
01/05/20057:30AMPR Newswire (US)Vicuron Pharmaceuticals to Present at the 23rd Annual JP Morgan Healthcare ConferenceNASDAQ:MICU
12/21/20044:30PMPR Newswire (US)Vicuron Pharmaceuticals Submits New Drug Application for Dalbavancin to U.S. Food and Drug AdministrationNASDAQ:MICU
11/29/20047:30AMPR Newswire (US)Vicuron Pharmaceuticals to Present at the Lazard Freres & Co. Healthcare ConferenceNASDAQ:MICU
11/04/20044:30PMPR Newswire (US)Vicuron Pharmaceuticals Announces Third Quarter 2004 Financial ResultsNASDAQ:MICU
11/01/20042:00AMPR Newswire (US)Vicuron Pharmaceuticals Announces Data at ICAAC Supporting Next-Generation Lincosamide ProgramNASDAQ:MICU
11/01/20042:00AMPR Newswire (US)Vicuron Pharmaceuticals Announces Data at ICAAC Demonstrating Potency of Anidulafungin and DalbavancinNASDAQ:MICU
10/25/20048:30AMPR Newswire (US)Vicuron Pharmaceuticals Announces 40 Presentations at ICAAC Highlighting Pipeline and Late-Stage ProductsNASDAQ:MICU
 Showing the most relevant articles for your search:NASDAQ:MICU

Your Recent History

USOTC
KITL
Kisses from Italy (QB)
USOTC
CLNV
Clean Vision (QB)
USOTC
UBQU
Ubiquitech Software (PK)
COIN
XRPUSD
Ripple
USOTC
RNVA
Rennova Health (PK)
NASDAQ
COOP
Mr Cooper
NYSE
GME
GameStop
USOTC
IGPK
Intergrated Cannabis Sol... (PK)
USOTC
ENZC
Enzolytics (PK)
USOTC
HIRU
Hiru (PK)
USOTC
FNMA
Fannie Mae (QB)
USOTC
AXXA
Exxe (PK)
AMEX
SPY
SPDR S&P 500
USOTC
SMCE
SMC Entertainment (PK)
NASDAQ
AVXL
Anavex Life Sciences
USOTC
RDGL
Vivos (QB)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved